T
Tectonic Therapeutic
Transforming the discovery of novel drugs addressing targets in the GPCR family
About Tectonic Therapeutic
Tectonic Therapeutic is a biotech startup co-founded by Andrew Kruse and Tim Springer of Harvard Medical School. The company is focused on the discovery and development of antibodies and other biologic drugs that target G-protein Coupled Receptors (GPCRs). GPCRs are a large class of proteins that play a key role in many biological processes and are the target of a large number of drugs. However, some GPCRs have been difficult to target with drugs, and Tectonic is working to change that.
The company's proprietary GEODe™ platform is designed to target these previously "undruggable" receptors, with the aim of developing new treatments for a wide range of patients with unmet medical needs. In other words, Tectonic is trying to find new ways to treat diseases that currently have no effective treatments.
Tectonic operates in the biotech market, serving clients in the healthcare and pharmaceutical industries. The company's business model is based on the research and development of new drugs, which it then aims to commercialize either by selling the drugs directly or by licensing them to larger pharmaceutical companies.
The company is led by a team of experienced executives and scientists, including President and CEO Alise Reicin, M.D., and Chief Scientific Officer Peter McNamara, Ph.D. The company's co-founder, Tim Springer, was recently awarded the 2022 Lasker Award, a prestigious recognition in the field of medical research.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Watertown, United States
- Employees
- 68
- Open positions
- None listed
- Dealroom signal
- 49.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Feb 2025 | $185M | — | EcoR1 Capital · StemPoint Capital · TAS Partners · Adage Capital | ↗ |
| IPOOther financing | Jan 2024 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Tectonic Therapeutic is 4.7K monthly website visits, down 2.1% over the last three months. Tectonic Therapeutic's team grew 7.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Polaris Partners
Vida Ventures
EcoR1 Capital- TST.A. Springer
Other known investors11 additional known investors
- TPTAS Partners
5AM Ventures
Adage Capital
Ally Bridge Group
Deep Track Capital
Farallon Capital Management
Harvard University- PGPags Group
- SCSoleus Capital
StemPoint Capital
Woodline Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tectonic Therapeutic on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tectonic Therapeutic’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.